Katsuki Yoko, Takata Minoru
Laboratory of DNA Damage SignalingDepartment of Late Effects Studies, Radiation Biology Center, Kyoto University, Yoshidakonoecho, Sakyo-ku, Kyoto, Japan.
Laboratory of DNA Damage SignalingDepartment of Late Effects Studies, Radiation Biology Center, Kyoto University, Yoshidakonoecho, Sakyo-ku, Kyoto, Japan
Endocr Relat Cancer. 2016 Oct;23(10):T19-37. doi: 10.1530/ERC-16-0221. Epub 2016 Aug 22.
Hereditary breast and ovarian cancer (HBOC) syndrome and a rare childhood disorder Fanconi anemia (FA) are caused by homologous recombination (HR) defects, and some of the causative genes overlap. Recent studies in this field have led to the exciting development of PARP inhibitors as novel cancer therapeutics and have clarified important mechanisms underlying genome instability and tumor suppression in HR-defective disorders. In this review, we provide an overview of the basic molecular mechanisms governing HR and DNA crosslink repair, highlighting BRCA2, and the intriguing relationship between HBOC and FA.
遗传性乳腺癌和卵巢癌(HBOC)综合征以及一种罕见的儿童疾病范可尼贫血(FA)是由同源重组(HR)缺陷引起的,并且一些致病基因存在重叠。该领域的最新研究带来了PARP抑制剂作为新型癌症治疗药物的令人兴奋的发展,并阐明了HR缺陷性疾病中基因组不稳定和肿瘤抑制的重要潜在机制。在这篇综述中,我们概述了控制HR和DNA交联修复的基本分子机制,重点介绍了BRCA2,以及HBOC和FA之间的有趣关系。